Emami Limited (531162) Earnings Call Transcript
November 10, 2025
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Emami Ltd Q2 FY26 earnings conference call, which is being hosted by IIFL Capital Services Ltd. Please be reminded that every participant line will remain in listen-only mode, and once the presentation wraps up, you'll have a chance to pose your questions. If you require any help while the call is underway, just press star then zero on your touchtone phone to signal an operator. Kindly be aware that this conference is being recorded. At this point, I'll turn the conference over to Mr. Percy Panthaki of IIFL Capital Services Ltd. Thank you, and over to you, sir.
Hello everyone, and good evening. We're glad to host the Q2 FY2026 conference call for Emami. Joining us today are Mr. Mohan Goenka, Wholetime Director and Vice Chairman; Mr. Vivek Dhir, CEO, International Business; Mr. Gul Raj Bhatia, President, Healthcare; Mr. Manish Gupta, President, Sales; Mr. Giriraj Bagri, Chief Growth Officer; and Mr. Rajesh Sharma, President, Finance and IR. I'll now turn the call over to Mr. Goenka, who will walk you through the results. Over to you, sir.
Thank you, Percy. Good afternoon, everyone — ladies and gentlemen. We appreciate your time in joining the Emami Ltd Q2 FY2026 earnings call today, covering the quarter and the half year that closed on 30th September 2025. During this quarter, the government of India brought forward a policy change of a transformational nature, cutting GST rates throughout major FMCG categories. It's a landmark reform, one designed to boost affordability, strengthen consumers' purchasing power, and in the end spur consumption that is broad-based across urban and rural India alike. For Emami, this reform is structurally positive, since almost 88% of our core domestic portfolio gained from the GST reduction — from 12% or 18% down to 5% now — which lifts the share of our portfolio covered by the 5% GST rate to roughly 93%. True to our consumer-first philosophy, we moved quickly to pass along the benefits of this rate cut, strengthening our dedication to affordability driven by value as well as accessibility. Although this reform establishes the groundwork for demand acceleration over the long term, putting it into effect brought temporary trade disruptions during September. Trade channels and consumers held back purchases while anticipating lower MRPs, and distributors concentrated on clearing out higher cost inventory, which produced a short-term softening in sales. The timing of the GST rate change also overlapped with the peak winter pipeline build-up, which led to a deferment in loading our winter portfolio.
On top of that, our summer portfolio had a tough second quarter — the second one in a row — because of heavy rains, and that really hit demand in the category, especially for talc and prickly heat powders. Since we'd posted our best-ever second-quarter sales in the talc and prickly heat powder category a year earlier, a softer market combined with that high base produced a sharp year-on-year drop this quarter. So consolidated revenues came in at INR 799 crore, down 10% this quarter, driven by a 15% fall in the domestic business. That said, outside the categories affected by GST rates, some of our portfolio that isn't impacted by GST rates put up encouraging growth: the Medico range rose 8%, Zandu Cough Syrup 43%, Honey 36%, and Zandu Care 17%. Our strategic investment portfolios also bounced back, growing 16% year on year and 36% sequentially, which reflects better performance across our key focus areas. Our approach of purposeful innovation and premiumization keeps gaining traction. A year ago we made a bold move, transforming Fair And Handsome into Smart And Handsome and positioning it as a complete men's grooming brand. This quarter we went further on that journey, launching 12 new products across different categories. Our initial rollout across modern trade and e-commerce platforms has been encouraging.
We also recently did a strategic relaunch of Kesh King as Kesh King Gold, grounded in deep consumer research that showed a shift in expectations. Our Ayurvedic heritage remains our biggest strength, but today consumers also want the added assurance of science and proof of efficacy. That insight led us to evolve the Kesh King proposition to Ayurveda plus science, building on our legacy while enhancing credibility and relevance among modern consumers. Our international business delivered steady 8% growth despite persistent macro and geopolitical headwinds. Our approach remains one of strategic focus, combining portfolio relevance, market-specific innovation, and localized execution excellence to drive sustained value creation globally. On the financial front, gross margins remain stable at 71%, underscoring our cost discipline and input price stability. EBITDA for the quarter stood at INR 179 crores, declining by 29%, and PAT at INR 148 crore, declined by 30%, reflecting the temporary impact of lower top line. The Board of Directors also declared an interim dividend of 400%, amounting to INR 4 crore per share for FY2026. Looking ahead, I am pleased to share that October has witnessed a healthy rebound in trade sentiments, with the deferred winter loading being recovered, placing us on a strong footing for the second half of the year.
Our outlook for a strong and profitable second half stays positive. Several things support that view: a favorable winter season, trade getting back to normal after the GST reform, and the good effect of the strategic steps we have taken. Organized channels keep expanding, and that, along with our operational agility and cost leadership, makes us even more confident. Taken together, these levers put us in a good position to deliver sustained profitable growth in the second half and to strengthen the foundation for long-term value creation and market leadership. With that, I would now like to open the floor for questions.
Thanks a lot. At this point we'll move into the question-and-answer portion. If you'd like to pose a question, you can hit star and one on your touchtone phone. Should you want to drop out of the queue, just press star and two. We ask that participants use their handsets when asking a question. Ladies and gentlemen, we'll hold for a brief moment while the queue comes together. Participants, please go ahead and press star and one to ask a question. Our first question comes from Percy Panthaki at IIFL Capital Services. Please go ahead.
Sir, could you share a bit more detail on the Navratna relaunch? Beyond the new name, what other adjustments have you made to the marketing mix?
That's not Navratna, Percy — it's Kesh King.
My apologies — Kesh King, that's right.
Right, right. So Kesh King is a purely Ayurvedic-based product—or was, rather. Naturally, we brought science into Ayurveda. What we did was strengthen and improve those formulations by adding ingredients such as Grobiotin and Plant Omega 369, both of which are scientifically proven, you know, to boost the results. So today it's a purely Ayurvedic formulation with science backing it. That has paid off. We launched it last month. I think the market has received it well. Naturally, a massive advertising campaign will support it. The launch was delayed somewhat because of the GST disruptions, but at this point we are fully on it.
Is the new formulation going to be included in the communication message?
Yes, 100%.
Understood, understood. Yeah, operator, I believe we’re ready to take questions from the queue.
Thanks a lot. Our next question comes from Nitin Gupta at Emkay Global, on the line. Go right ahead.
Thanks for taking my question. First, on that GST-related de-stocking of 4% in Q2, I just wanted to get a sense of whether it can be fully recovered in Q3, or whether you think it will take some time?
Nitin, we have a lot of confidence that this will be recovered in Q3. We've already seen some recovery in October itself, since we weren't able to load it during the final days of September, and that volume ended up being loaded in October.
From what you said at the start about Kesh King, you pointed to a change in expectations. As with several companies that have reported results — HUL, for instance, has made this point — we are in a sense generating growth in FMCG while they seek to align their portfolios. Since our portfolio has greater salience in rural areas, would you care to comment on how consumption trends are taking shape in the rural market?
Absolutely, Nitin. I'd say that lately we've been seeing solid demand emerge from rural areas across every one of our categories. When it comes to Kesh King, our real emphasis has been on the shampoo sachets, specifically using them to fuel sachet growth. That formed part of the plan, and the results we're seeing are excellent — it's driving sachet growth in rural markets, especially in shampoo.
Thanks. On Smart And Handsome, we’re expanding into several categories. Are the core face cream categories facing structural pressure? Also, I just wanted to get a sense — since we’re positioning this brand in modern trade and e-commerce, will there be any cannibalization risk for TMC?
Not really. They sit at completely different price points and fall into entirely separate categories. It won't be going up against The TMC. Yes, definitely — a structural shift is underway. That's the reason such bold steps are being taken. Demand for face cream isn't as high as it once was, but with these new offerings, I'm confident that overall we will gain.
Alright, that's useful. And finally, if you could offer a few remarks about your winter loading at this point and how you see the winter taking shape. Thanks.
Winter has settled in really nicely across the region, especially in the north, the east, and the western central area as well. Loading, naturally, has come in above what we expected, since we weren't able to load during September, but October got off to a great start. We're anticipating a strong winter this year, so we're fully prepared and ready for it.
Absolutely, sir. Thank you. Many thanks, and all the best to you.
Thanks. Listeners, if you'd like to ask something, hit star and then one. Our following question comes from Harit Kapoor at Investec. Go right ahead.
Hello, and good evening. My first question was also about the edge. When you look at quarter three, there are a couple of factors that hit you in quarter two that are almost fully reversing — namely the -4% on the GST impacted portfolio and a further -4% on the winter loading. I just wanted to get your view on whether we see this kind of strong double-digit growth figure because some of those impacts in Q2 stayed away or came in during Q3 itself? That is the first question. Beyond that, for this year's -10% number for the consolidated revenue, how much of that would have been the volume decline? That is my first question.
Harit, in the second quarter we clearly saw a significant loss in our summer portfolio as well, which I mentioned earlier. That came to roughly 4%–4.5%. Right. And nearly 4%–4.5% of it happened because we weren't able to load the winter products. What we lost in summer obviously can't be recovered in these quarters. As for winter loading, like I said, we've pushed as hard as we could during October, and distributors have responded quite favorably. I'm very confident that in the third quarter we will definitely see a better outcome — much better than what we've seen before. I'm certainly expecting something close to double digit, but high single digit is 100% on the cards.
Understood, understood. Regarding growth in volume, what would that volume decrease come to? Roughly what figure would that be? If you could just give me the effect of pricing on total revenue, whichever direction it goes.
In the domestic business, total volume was down about 16%.
Understood. Understood.
Harit, this was the one-off quarter. All right.
Yes, absolutely.
That shouldn’t be the case, and there are several reasons why. I’m quite confident we will rebound in the second half, apart from the summer portfolio that everybody has lost.
Understood. The next item concerned the strategic investment.
Apologies, I’m unable to hear you. I’m unable to hear you.
Okay, is this coming through clearly at this point? Does that sound any clearer?
Yeah, yeah.
And then the second item concerned our strategic investments portfolio. That portfolio has seen a robust recovery in growth. I just wanted to understand, on a quarter-on-quarter basis as well, whether you have observed this improvement. Is some of it coming from a somewhat low base, which would have helped? If so, this improvement on the ground — what is actually driving it? I recall that in the last quarter, all of you mentioned considerable competitive intensity, discounting and so on. Could you break that down into which green shoots you are seeing there?
Giriraj is with us. Giriraj, could you shed some light on the strategic investments?
Yes, hello. To address the first portion of your question, on a sequential basis, the past six quarters have delivered our strongest sales and growth. That momentum, we believe, will pick up further in the quarter ahead — the Q&A quarter. So that covers where strategic investments stand in terms of their growth trajectory. For the second half, we anticipate the business expanding at an even faster pace than the first half — a strong double digit rate. As for what drove this growth, there are fundamentally a few factors at play. First, we've stepped up spending behind both brands, Brillare and TMC. With fresh communication, we now have a new influence of Flywheel that is beginning to take effect at this point. Among the channel gains worth noting for this quarter are quick commerce, modern trade, and our own D2C websites, all of which posted strong growth. The marketplaces likewise turned in strong growth. They might have done even better were it not for the GST disruption that Mohan G. mentioned, particularly at one of the large players, whose warehouses were entirely choked and therefore could not take stocks in.
Overall, I'd say that across both product categories and channels, aside from one or two channels, we've witnessed really impressive growth, and we anticipate that this momentum will pick up speed during the second half.
Understood. Final question: from the standpoint of low unit packs, where grammage increases would likely have been chosen instead of price reductions, does that form a significant portion of the portfolio? And if it does, what share, and across which categories would that apply?
This applies across the whole category. As I mentioned, GST rates shifted for nearly 90% of what we sell. For each small SKU, we've raised the grammage. That adds up to roughly 20% or so.
Alright, 20%.
Yeah.
Understood. I’ll return for additional questions. Thank you. Thank you.
Thanks. Our following question comes from Arnab Mitra at Goldman Sachs. Your line is open.
Yes, hi Mohan G. You talked about winter loading being recovered in 3Q, but what about the GST-affected portfolio, where destocking also happened? Do you feel that will recover as well, or might the pipelines take a bit more time to come back there?
Arnab, October showed a solid rebound for us, alright, and the first 10 days of November did as well. Should that pattern hold, my hope is that we get all the way back in Q3. If it carries on, then I'm confident we'll be fully recovered in the second half.
Understood. Understood. Mohan G., that was what we were expecting.
Fortunately, the winter season has gotten off to a positive start. That makes me quite pleased.
Mohan G., my next question ties into that. If winter loading comes back, you recover a portion of the pipeline, the winter season is favorable, and you've also introduced those initiatives on Kesh King, shouldn't we with real confidence expect double-digit growth in the third quarter? I'm just trying to get a handle on this — are there other concerns behind your comment that we might reach high single digit but not definitely double digit? I'd simply like to understand how you're viewing overall growth for the third quarter and for the second half as a whole.
I'm simply staying a bit cautious, Arnab, since as I mentioned, winter has begun on a very good note, but we're still heading into the winter season. Okay. You're right. I do have confidence in double digit. It's not that I lack it. Should winter continue in this manner, then nothing can prevent double digit, that's certain.
Understood. My final question concerned the GST reduction. In any category where you have observed a price decrease from the GST cut, do you feel that fundamentally it could support better growth—whether through the unorganized segment, the organized segment, or the actual elasticity of demand?
I'm confident, Arnab, that this will apply across categories — balms, oils, all of them. Look, on the whole, within Emami's domestic business alone, we've seen MRP reductions of roughly INR 260 crore. Consumers are going to receive that benefit. It should certainly be helpful. Now, exactly where it helps and by how much is very hard for me to state, but improvement should begin before long.
Understood. My previous question concerned margins. Naturally, operating deleverage affected you this quarter. Looking forward, could you help us understand gross margins — what is the situation with input costs, and how ought we to view second-half margins versus the prior year, taking into account both input costs and the growth you believe you can achieve?
Arnab, on the input side, there's really no pressure at all. It's well under control. And margins are definitely going to improve. Like I said, Q2 is one we can write off. It's not the best Q2, you can remove that. But I'm sure there would be expansion in margin. There would be high growth in our EBITDA margins and net margins in Q3. Other than the summer, we're going to recover everything in this quarter.
Understood. Understood. Thanks. That's all from me. Best of luck.
Thanks. Anyone who’d like to ask a question can press star and one. We’ll now take the next question from Kshitij Shah at Avendus Spark Institutional Equities. Please go ahead.
Hi, Mohan G. Thanks for the chance to ask. Mohan G., I came in a little late, so sorry if this was already covered or answered earlier, but is there any distribution expansion or distribution reform that we're undertaking right now?
Yes, Manish will take that one.
Hi, Manish speaking. As we've noted during several calls over recent quarters, from a distribution standpoint our key focus remains modern trade, e-commerce, and QC channels, since that's where consumer behavior is shifting. We're already on that bandwagon, and as our results keep showing periodically, we're seeing solid, steady growth across these channels. These are where today's young shopper buys, and we're highly mindful of it. We keep putting substantial investment—both effort and personnel—into them. In traditional channels we're a robust system with a strong network, and we keep up our presence there. I mean, all our figures on presence, distribution, and similar metrics remain very solid. We keep investing on the ground, and our product presence is growing in step with category growth.
Understood. What’s our saliency at present when it comes to quick commerce?
E-commerce accounts for roughly 40% of that.
So then, how much will e-com be, and what portion of that would be empty?
Roughly 11% apiece. I'm referring to the domestic consumer business.
Understood. Now, on the distribution side: historically, we've consistently begun the winter season on a strong footing, yet in recent times volatility or a delayed winter has become quite a common occurrence. If winter does turn out to be volatile or delayed, are we positioned to capture that, say, in the fourth quarter as well?
Right, right. Look, if you look at last year, I think we had a fantastic winter. We're hoping — and this year, by our own internal estimates, winter is certain. The winter in the north, for example, is almost about two weeks earlier. We should be capitalizing on it. As Mohan G. explained earlier, we're already seeing the trade buoyancy around it, and we're well prepared because even in Q4 these days, winter extends a bit. It's not just about Q3. It's also about playing well in Q4.
Understood. Understood. One final question, Mohan G. — you mentioned the modifications made to Kesh King. I'd just like to understand what consumer insights we would have picked up recently, because if we look back over the last five, seven, or ten years, there was a period when Ayurveda was front and center, after which we shifted toward naturals. Then all at once, more recently, the emphasis is on efficacy-driven, science-based products. With a brand like Kesh King, my expectation as a consumer would center largely on Ayurveda or naturals. When we shift toward science-based positioning, does that amount to moving the brand's core, or do your surveys or insights indicate that this is very much acceptable for the brand's core as well?
This was a really significant step, since Kesh King was facing substantial pressure from D2C brands, especially in the hair fall segment. Right. And the majority of those D2C players are science-backed. That's what young consumers want. That's the direction the trend is heading. When it comes to hair fall, consumers continue trying these D2C brands. After carrying out all this research over the past nine, ten months, we discovered that Ayurveda is, naturally, still part of the picture. We aren't moving away from Ayurveda. If we support it with both Ayurveda and science, that will make a meaningful difference over the long run. That's the decision we made. Marketers accepted it. I think even the packaging or the ingredient story, advertising, we're going to begin very soon. I'm quite confident that the entire 360 plan we have for Kesh King should work.
Even regarding the efficacy that's been demonstrated, suppose that as a consumer, I'd vouch for it and recommend it to others too?
Each one of our products has undergone clinical testing. All of them. Whatever claims we put forward are backed by clinical proof.
All right, that's very clear. Thank you, and best of luck as you head over to our event.
Thanks. Our following question comes from Kunal Vora at BNP Paribas, on the line. Go right ahead.
Yes, thanks. I believe you touched on this, but could you make it clear what share of the portfolio you've raised grammage or milliliter on, and what share you've cut MRP on?
Twenty percent comes from higher grammage, and the rest is entirely lower MRP.
All right, so what does the consumer look like?
With sachets, every one of them is a grammage increase.
So sachets account for 20%, is that right?
Sachets, yes. For sure. For sure.
Okay, so with sachets — suppose the milliliter size goes up — would you be fine with that, or is there a chance the unit count drops somewhat?
Apologies, Kunal, I didn’t catch that part in between.
Right, so let's assume the sachet will now contain more ml. Would that cause the number of units you sell to drop somewhat, or should there be no effect at all?
My view is that this shouldn't have any effect.
Right. So that covers the entire transition.
Yeah. Navratna and the rest are meant for one-time use. So my sense is there won't be any meaningful impact from that. Yeah.
All right. In the places where you've cut prices, what sort of elasticity are you anticipating? From your perspective, how do consumers react when prices come down?
Conditions in the market remain uneven. Older inventory is still present. A portion of that older inventory remains, and it is, naturally, being cleared out now. Once the new MRP stock is fully in place across the entire GT and the rural markets, we have strong hopes. As I mentioned, within our own portfolio, in the domestic business, the MRP cut comes to nearly INR 250 crore, which is quite meaningful from the consumer's standpoint. We will see. We will need to wait and watch where consumer spending actually ends up, wherever they choose to save money. Just give it one more quarter and see.
All right, over the coming two, three, or, say, 4 quarters, suppose consumers aren't reacting to reduced prices by buying bigger volumes—would you then consider reversing that, or, say, at minimum nudging prices back up a bit?
We aren’t able to make that determination at this moment. We’ve just lowered our pricing.
Got it. Got it. Finally, what are your initial views on FY 2027? I mean, I realize the second half ought to be strong, but do you think the advantages from the GST rate cut will keep carrying into the future? Any preliminary sense of what FY 2027 might look like?
Yes, yes. Absolutely, Kunal. Like I mentioned, what would keep consumers from spending more in our categories? New consumers ought to certainly arrive from unorganized. We've reinforced every one of our pillars. Naturally, we will begin next year from a lower summer base as well, since we lost a great deal within the summer portfolio. FY 2027 ought to certainly be far better than FY 2026. There is no question about that.
Alright. That's all I've got. Thank you, sir.
Yeah. Thanks.
Thank you. Those wanting to pose a question can hit star and one. If you'd like to ask something, go ahead and press star and one at this time. Ladies and gentlemen, to submit a question, kindly press star and one.
Vivek, is there anything you'd like to say about the international business? We don't have any questions. Vivek is with us. Yeah, just.
Good evening, everyone. In our international business, we've observed what I'd call moderate expansion in nearly every market. In some markets, candy sales are actually running above the numbers we posted for primary sales. Primary sales stand at roughly 8%. A few markets have begun to pick up for us, and we're hoping for stronger gains across most geographies over the next few quarters. A lot of new NPDs are in the works, and those should soon come to market, which will help shape the future portfolio for us internationally. Nepal came in at almost 100%. Even with the disruptions, our growth there exceeded 100%.
Thanks. We'll take the next question from Akash Shah at UTI Mutual Fund. Your line is open.
Yeah, my question was about the international business in particular. So sir, if you could give us a broad sense of how growth has been across SAARC, MENA, and CIS, a broad range would be helpful too.
SAARC has performed extremely well for us. In the SAARC markets, Bangladesh included, we achieved growth of more than 22% there. The GCC and MENA markets have been pretty flat for us, mainly owing to one key market, Egypt, where we weren't able to accomplish much. The remaining markets have likewise posted reasonable growth in the marketplace. We are encountering problems in one or two markets, Egypt and Bahrain, which we are trying to address, and matters ought to improve soon in those markets. All of the growth in the international market has come across markets, for the most part.
Alright, yeah, sorry — just one last thing about the domestic side, meaning the Smart And Handsome range. Essentially, with this move into new categories, on the whole, how's the early feedback been? Any reactions, or, I mean, any first signals you've gotten from the market?
Right now, this is mostly at the test marketing stage. We've just launched it on one platform to see how the response is. We launched it on a platform just about last month. Let's see. We'll have to wait. Of course, we're going to roll it out on other e-comm sites and NMT. That hasn't been done yet, but we're very optimistic.
Alright. Alright. Of course. Appreciate it.
Thanks. If you'd like to ask a question, attendees, please press star and one.
Ma'am, Gul Raj is with us as well. He serves as CEO of the Health Care Division. Gul Raj, could you shed some light on the healthcare side?
Yes, Mr. Mohan G. Thank you. As Mr. Mohan G. said right at the beginning of this call, I believe that when you look at activity levels, the medical business delivered solid growth for us.
Gul Raj, I’m having trouble hearing you clearly.
Okay, is that improved at this point, sir?
Sure. Please, go right ahead.
Right. During the quarter just ended, we saw solid expansion from the medico segment — that's the Ayurvedic operation serving Ayurvedic physicians along with other doctor groups. Growth there came to roughly 8%. We also performed well on certain focus brands, including cough syrups and honey, and our direct-to-consumer platform, Zandu Care, posted fairly healthy growth too, given the difficulties that hit businesses around the GST cuts and so on. We feel quite positive about how this quarter is shaping up. We've launched efforts to grow our business in a few focus categories, which would sit within the Chyawanprash range. Focus will remain on certain growth driver categories — cough syrups, supplements, and some of our new D2C launches. In the OTC business as well, we expect an improved showing in quarter three. Meanwhile, in most categories, we're aiming to lift our market shares relative to other Ayurvedic competitors across those categories. We're undertaking numerous efforts to broaden our reach among doctors and retailers too. Thank you.
Thanks. Anyone who wants to ask something can hit star and one. Ladies and gentlemen, since no more questions are coming in from the participants, I’ll now turn the conference back over to management for closing remarks.
Thanks to all of you for being with us on this quarter two earnings call. Our thanks to IIFL. And thank you, Percy, for putting this together. Thank you. Have a good day. Many thanks to you all.
Thanks.
Thank you. That brings this conference to a close on behalf of IIFL Capital Services Ltd. We appreciate your participation, and you can disconnect your lines at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Emami Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Emami Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.